ABROCITINIB

Information current as at: 1 April 2026

PBAC meeting date: November 2021
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Cibinqo®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Condition/indication:
(therapeutic use)
  • Atopic dermatitis
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC submission type:
New listing (–)
Comment:
To be considered at a future PBAC meeting
Submission sponsor:
Pfizer Australia Pty Ltd
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2021 PBAC meeting
Opportunity for consumer comment:
Open 28/07/2021 and close 22/09/2021 (see PBS Website)
PBAC meeting:
Not applicable
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID: a389

Page last updated: 31 March 2026

v.9.19